Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:16 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal

NCT02894112
View directory record Official record
Conditions
Oral Glucose Tolerance Test, High Fat Tolerance Test
Interventions
non-fat milk, carbohydrate control beverage, caloric control beverage
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
20 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 2 Interventional Results available

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

NCT01928381
View directory record Official record
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions
AZD5213 + pregabalin, Placebo, pregabalin capsules
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Nov 1, 2026, 4:16 AM EST
Withdrawn Not applicable Interventional

Effect of a Plant Rich Diet on in People With Type 2 Diabetes and Obesity

NCT02977039
View directory record Official record
Conditions
Type 2 Diabetes Mellitus in Obese
Interventions
NDPR diet, USDA healthy eating diet
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

D-Cycloserine and Social Skills Training in Autism Spectrum Disorders

NCT01086475
View directory record Official record
Conditions
Autistic Disorder, Asperger's Disorder, Pervasive Developmental Disorder NOS
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 11 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Nov 1, 2026, 4:16 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Animal and Plant Proteins and Glucose Metabolism

NCT03994367
View directory record Official record
Conditions
Metabolic Syndrome, Metabolic Syndrome, Protection Against, Glucose Metabolism Disorders
Interventions
High animal protein isolate, High animal protein whole food, High plant protein isolate, High plant protein whole food
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 2 Interventional Results available

D-cycloserine in the Management of Chronic Low Back Pain

NCT00125528
View directory record Official record
Conditions
Low Back Pain, Pain
Interventions
D-cycloserine, placebo
Drug
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Nov 1, 2026, 4:16 AM EST
Terminated Phase 4 Interventional Results available

Simplified Insulin Regimen for the Elderly

NCT03660553
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Glargine, Insulin Aspart, Insulin Lispro
Drug
Lead sponsor
University of Miami
Other
Eligibility
65 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Nov 1, 2026, 4:16 AM EST
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

NCT01646177
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, 50 mg etanercept, 80 mg ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
41
States / cities
Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 3 Interventional

Cystic Fibrosis - Insulin Deficiency, Early Action

NCT01100892
View directory record Official record
Conditions
Cystic Fibrosis, Diabetes
Interventions
Once-daily insulin detemir
Drug
Lead sponsor
Sydney Children's Hospitals Network
Other
Eligibility
5 Years to 19 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 3 Interventional Results available

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT04523129
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 3 Interventional Results available

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

NCT00082628
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Placebo, Serostim® 4 mg, Serostim® 2 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

NCT00097877
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
71
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 1 Interventional

Omalizumab for Lupus

NCT01716312
View directory record Official record
Conditions
Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 2Phase 3 Interventional Results available

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

NCT04824365
View directory record Official record
Conditions
COVID-19
Interventions
Sodium Pyruvate, Saline
Drug · Other
Lead sponsor
Cellular Sciences, inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Virginia Gardens, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

NCT03211234
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Nov 1, 2026, 4:16 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

NCT00485134
View directory record Official record
Conditions
Shigellosis
Interventions
240 µg Shigella flexneri 2a Invaplex 50 vaccine, 480 µg Shigella flexneri 2a Invaplex 50 vaccine, 690 Shigella flexneri 2a Invaplex 50 vaccine, Shigella challenge strain
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Nov 1, 2026, 4:16 AM EST
Terminated Phase 2 Interventional

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

NCT00766337
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Sirolimus in combination with ranibizumab, Placebo in combination with ranibizumab
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Nov 1, 2026, 4:16 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Regulation of Reproductive Hormones in Adult Men

NCT00392457
View directory record Official record
Conditions
Kallmann Syndrome, Hypogonadism, Gonadal Disorder
Interventions
ketoconazole, gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Nov 1, 2026, 4:16 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Tyrosol and Creatine on Endurance, Strength, and Fatigue Resistance in Healthy Adults

NCT06883292
View directory record Official record
Conditions
Tyrosol, Creatine, Endurance Performance, Cognition
Interventions
Tyrosol, Creatine, Resistant Dextrin
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Nov 1, 2026, 4:16 AM EST
Completed Not applicable Interventional

The Peds Obesity Study

NCT02353637
View directory record Official record
Conditions
Pediatric Obesity
Interventions
Partial Meal Replacements
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Nov 1, 2026, 4:16 AM EST
Terminated Phase 2 Interventional

Increased Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids

NCT01821430
View directory record Official record
Conditions
Chronic Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Nov 1, 2026, 4:16 AM EST